$514 Million is the total value of Octagon Capital Advisors LP's 28 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was - .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
ITOS | New | ITEOS THERAPEUTICS INC | $20,988,000 | – | 450,776 | +100.0% | 4.08% | – |
KROS | New | KEROS THERAPEUTICS INC | $19,906,000 | – | 340,214 | +100.0% | 3.87% | – |
KDNY | New | CHINOOK THERAPEUTICS INC | $8,155,000 | – | 500,000 | +100.0% | 1.59% | – |
IMVT | New | IMMUNOVANT INC | $4,881,000 | – | 572,862 | +100.0% | 0.95% | – |
OLMA | New | OLEMA PHARMACEUTICALS INC | $2,166,000 | – | 231,417 | +100.0% | 0.42% | – |
CMPX | New | COMPASS THERAPEUTICS INC | $761,000 | – | 240,000 | +100.0% | 0.15% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
APELLIS PHARMACEUTICALS INC | 12 | Q3 2023 | 33.2% |
ARCUS BIOSCIENCES INC | 12 | Q3 2023 | 18.1% |
CELLDEX THERAPEUTICS INC NEW | 12 | Q3 2023 | 10.1% |
GOSSAMER BIO INC | 12 | Q3 2023 | 6.2% |
4D MOLECULAR THERAPEUTICS IN | 10 | Q1 2023 | 6.6% |
BRIDGEBIO PHARMA INC | 10 | Q3 2023 | 6.6% |
AVIDITY BIOSCIENCES INC | 10 | Q1 2023 | 3.8% |
VERA THERAPEUTICS INC | 9 | Q2 2023 | 3.5% |
DYNE THERAPEUTICS INC | 9 | Q3 2023 | 3.5% |
STOKE THERAPEUTICS INC | 9 | Q2 2023 | 3.7% |
View Octagon Capital Advisors LP's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-06 |
SC 13G/A | 2024-02-05 |
SC 13G | 2024-02-05 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-14 |
13F-HR | 2023-05-15 |
13F-HR | 2023-02-14 |
SC 13G | 2023-01-25 |
13F-HR | 2022-11-14 |
View Octagon Capital Advisors LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.